Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection

Stephen R. Smalley, Jacqueline K. Benedetti, Daniel G. Haller, Scott A. Hundahl, Norman C. Estes, Jaffer A. Ajani, Leonard L. Gunderson, Bryan Goldman, James A. Martenson, J. Milburn Jessup, Grant N. Stemmermann,† Charles D. Blanke, and John S. Macdonald

See accompanying editorial on page 2297

Stephen R. Smalley, Radiation Oncology Center of Olathe, Olathe, KS; Jacqueline K. Benedetti, SWOG Statistical Center; Bryan Goldman, Fred Hutchinson Cancer Research Center, Seattle, WA; Daniel G. Haller, University of Pennsylvania Cancer Center, Philadelphia, PA; Scott A. Hundahl, University of California at Davis, Davis; John S. Macdonald, Aptium Oncology, Los Angeles, CA; Norman C. Estes, University of Illinois College of Medicine, Peoria, IL; Jaffer A. Ajani, MD Anderson Cancer Center, Houston, TX; Leonard L. Gunderson, Mayo Clinic in Arizona, Scottsdale, AZ; James A. Martenson, Mayo Clinic, Rochester, MN; J. Milburn Jessup, Diagnostics Evaluation Branch, National Cancer Institute, Rockville, MD; Grant N. Stemmermann, University of Cincinnati, Cincinnati, OH; and Charles D. Blanke, The British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada.

†Deceased.

Submitted May 20, 2011; accepted February 29, 2012; published online ahead of print at www.jco.org on May 14, 2012.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Corresponding author: Stephen R. Smalley, MD, Radiation Oncology Center of Olathe, 20375 West 151st St, Suite 180, Olathe, KS 66061; e-mail: s_smalley@msn.com

© 2012 by American Society of Clinical Oncology

0732-183X/12/3019-2327/\$20.00

DOI: 10.1200/JCO.2011.36.7136

A B S T R A C T

Purpose

Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures. We performed a randomized phase III trial of postoperative radiochemotherapy in those at moderate risk of locoregional failure (LRF) following surgery. We originally reported results with 4-year median follow-up. This update, with a more than 10-year median follow-up, presents data on failure patterns and second malignancies and explores selected subset analyses.

Patients and Methods

In all, 559 patients with primaries $\geq$ T3 and/or node-positive gastric cancer were randomly assigned to observation versus radiochemotherapy after R0 resection. Fluorouracil and leucovorin were administered before, during, and after radiotherapy. Radiotherapy was given to all LRF sites to a dose of 45 Gy.

Results

Overall survival (OS) and relapse-free survival (RFS) data demonstrate continued strong benefit from postoperative radiochemotherapy. The hazard ratio (HR) for OS is 1.32 (95% CI, 1.10 to 1.60; $P = .0046$). The HR for RFS is 1.51 (95% CI, 1.25 to 1.83; $P < .001$). Adjuvant radiochemotherapy produced substantial reduction in both overall relapse and locoregional relapse. Second malignancies were observed in 21 patients with radiotherapy versus eight with observation ($P = .21$). Subset analyses show robust treatment benefit in most subsets, with the exception of patients with diffuse histology who exhibited minimal nonsignificant treatment effect.

Conclusion

Intergroup 0116 (INT-0116) demonstrates strong persistent benefit from adjuvant radiochemotherapy. Toxicities, including second malignancies, appear acceptable, given the magnitude of RFS and OS improvement. LRF reduction may account for the majority of overall relapse reduction. Adjuvant radiochemotherapy remains a rational standard therapy for curatively resected gastric cancer with primaries T3 or greater and/or positive nodes.

J Clin Oncol 30:2327-2333. © 2012 by American Society of Clinical Oncology

INTRODUCTION

In the 1990s, Intergroup 0116 (INT-0116), a randomized phase III trial, was conducted to compare observation versus adjuvant radiochemotherapy following curative gastric cancer resection. Before the initiation of INT-0116, survival following curative surgery had changed little in the prior three decades. The American College of Surgeons¹ and National Cancer Data Base^{2,3} reported large co-

horts resected in the 1980s and 1990s. Five-year survival ranged from 29% to 37% in stage II and 13% to 20% in stage III, depressingly similar to data from the late 1950s and 1960s.⁴⁻⁶ Postoperative adjuvant chemotherapy was extensively tested with disappointing results in Western patients. Some meta-analyses reported no significant benefit with postoperative chemotherapy;⁷⁻⁹ others found benefit either confined to¹⁰ or driven by Asian trials.^{11,12}

Strategies to decrease locoregional failure (LRF) have also been explored. Surgical series document LRF in 40% to 60% of patients in stage II or III disease.^{5,13-15} LRF consistently occurs in the tumor bed, anastomosis, and undissected regional nodes in these clinical, reoperative, and autopsy series. Surgical trials have attempted to reduce the nodal component of LRF by more comprehensive nodal resection. All five phase III trials that examine various degrees of Japanese D-level guided nodal surgery report higher operative morbidity and/or mortality with more extensive procedures but no convincing increase in survival.¹⁶⁻²⁰ Several reports of aggressive nodal surgery continued to observe substantial LRF.^{5,15,16} The Dutch randomized trial reported LRF in 58% with D1 and 45% with D2 dissection.¹⁶ This suggested that a more comprehensive strategy to address all LRF sites was needed. INT-0116 investigated whether postoperative adjuvant radiochemotherapy in patients with completely resected tumors but at substantial risk of LRF would improve relapse-free survival (RFS) and overall survival (OS). Previous methodologically flawed evaluations of adjuvant radiotherapy observed reduced LRF,²¹⁻²³ which may improve OS.^{21,22} Quality assurance problems with radiotherapy had been described,²³ requiring a robust radiotherapy quality assurance program. This study's primary analysis in 2001 demonstrated significant improvement in RFS and OS with adjuvant radiochemotherapy.²⁴ This update, with more than 10 years of follow-up, confirms the benefits of radiochemotherapy and explores associations of this type of therapy in selected subsets of patients with resected gastric cancer.

PATIENTS AND METHODS

Details of INT-0116 have been previously reported.²⁴ Eligibility criteria included R0 resection of adenocarcinoma of the stomach or gastroesophageal junction (GEJ), presence of complete penetration of the tumor through the muscularis propria and/or involved regional nodes (including 1988 American Joint Committee on Cancer [AJCC] stages IB to IV with M0), performance status 0 to 2, more than 1,500 kcal/d intake, and adequate general medical condition and laboratory parameters. Institutional review board–approved informed consent was obtained, registration occurred 20 to 41 days postoperatively, and treatment began within 7 working days of registration.

Treatment Plan

Patients were randomly assigned to surgery alone versus postoperative radiochemotherapy. Radiochemotherapy consisted of bolus fluorouracil (FU) and leucovorin (LV) before, during, and after radiotherapy. FU 425 mg/m²/d and LV 20 mg/m²/d on days 1 through 5 began on day 1. Radiation to a total of 45 Gy (1.8 Gy/d 5 d/wk for 5 weeks) began on day 28. FU 400 mg/m²/d and LV 20 mg/m²/d was given the first four and the last three days of radiotherapy, beginning 1 month after radiotherapy, two additional cycles of FU + LV were given once every 28 days. Radiotherapy targeted common LRF sites such as the tumor bed, regional nodes, and anastomoses. Nodal volumes were previously described.²⁴ The radiotherapy plan required approval by the radiation-oncology coordinator (S.R.S.) before radiotherapy could be initiated. Because of excessive toxicity risk, 9.5% of initial plans were rejected but all were corrected before radiotherapy. At initial review, 35% of treatment plans contained major or minor protocol deviations and most were corrected before the start of radiotherapy. Final quality assurance review (conducted after the delivery of radiation) revealed major deviations in 6.5% of the treatment plans.

Statistical Analysis

INT-0116 was designed to accrue 550 eligible patients, which ensured 90% power to detect a 40% difference in OS (hazard ratio [HR] of 1.4) and a 40% difference in RFS. The two stratification factors, T stage (T1-2 v T3

v T4) and N stage (N0 v one to three positive nodes v > three positive nodes), were included as covariates in the Cox regression analysis. All eligible patients were included in the OS and RFS analyses according to the intention-to-treat principle.

Patterns of failure (POF; based on Notice of Recurrence form required at first failure indicating all relapse sites and means of detection) were classified (J.S.M.) as follows: local if tumor relapsed in the surgical anastomosis, residual stomach, or gastric bed; regional if tumor recurred in the peritoneal cavity (including the liver, intra-abdominal lymph nodes, and peritoneum); and distant for relapse outside the peritoneal cavity. Relapse patterns were compared by using the χ^2 test. Histologic evaluation was centrally reviewed (G.N.S.). We also explored the effect of therapy by selected patient characteristics: sex, race, T stage, N stage, D level of nodal surgery, site of the primary tumor in the stomach (proximal or other), histology (diffuse or intestinal),^{24a} and Maruyama index (MI).²⁵ This was initially done by including a treatment-by-characteristic interaction in the Cox regression model. Lack of a significant interaction suggested insufficient evidence for selective treatment effects by level of the variable. To further explore potential relationships between treatment and variables, we estimated the treatment effects separately within levels of the factors (presented as forest plots). Where interaction terms were nonsignificant, it should be stressed that these individual analyses need to be interpreted with caution. *P* values are two-sided.

RESULTS

In all, 603 patients were registered from 1991 to 1998. Forty-four (8%) were ineligible because of positive surgical margins or nonadenocarcinoma histology, or they registered after the specified time limit. Of the 559 eligible patients, 277 were randomly assigned to observation and 282 to radiochemotherapy. Among those last known alive (*n* = 121), median follow-up was 10.3 years. GEJ primaries occurred in approximately 20% of patients. Patients had a high risk of LRF (more than two thirds of patients had stage T3,4 primaries, and 85% had nodal metastases).

Treatment

In the group that received radiochemotherapy, 182 (65%) completed planned treatment, 49 (17%) stopped treatment because of toxicity (23 of these 49 received ≥ 40 Gy), 5% progressed during treatment, 1% died during therapy, and 4% discontinued treatment for other reasons. Twelve percent (8% assigned to treatment; 4% assigned to observation) declined to continue the assigned therapy, but they are included in the assigned study group according to intention to treat (CONSORT diagram; Fig 1).

Surgical Procedures

A form defining the extent of lymphadenectomy was required before surgery. In all, 552 patients had a review of nodal dissection type; 54 (9.6%) received D2 dissection; 199 (36%) received D1 dissection (removal of Japanese N1 nodal stations), and 54% received a less than D1 dissection (resection of less than Japanese N1 nodal groups).

Toxicity

Acute toxicity. Acute toxicity effects were previously reported, the predominate types being hematologic and gastrointestinal. Four patients (1%) died secondary to therapy: two before radiation therapy (one from cardiotoxicity, one from neutropenic sepsis), one from radiation pulmonary fibrosis, and one from central line fungemia.

Fig 1. CONSORT diagram. OS, overall survival; RFS, relapse-free survival. (*) All 277 patients randomly assigned to observation and 282 patients randomly assigned to radiochemotherapy are included in the assigned study group according to the intention to treat in RFS/OS analyses

Long-term toxicity. We had no reports of excess treatment-related toxicities during long-term follow-up. Table 1 lists second malignancies. In the radiochemotherapy arm, there were 21 patients (representing 25 separate cancers) with second malignancies versus

eight in the observation group ($P = .21$). These results must be viewed with caution, because there is potential bias by treatment arm for completeness of reporting for second primaries.

Survival and Relapse Sites

With more than 10 years of follow-up, the OS and RFS data demonstrate continued strong benefit from postoperative radiochemotherapy. HRs were virtually unchanged since the original report. HR for OS (Fig 2A) was 1.32 (95% CI, 1.10 to 1.60; $P = .0046$), and the HR for RFS (Fig 2B) was 1.51 (95% CI, 1.25 to 1.83; $P < .001$). This shows highly significant benefit for radiochemotherapy. POF comparison was a prespecified major objective of INT-0116 and the details are provided in Table 2. χ^2 comparison for relapse versus no relapse had $P < .001$. For sites of relapse (among patients for whom sites were reported), χ^2 test for trend had $P = .012$.

Tests of Interaction and Exploration of Patient Subsets

Exploratory subgroup analyses were carried out for the following factors: sex, race, T stage, N stage, D level of resection, primary tumor location, histology, and MI. Forest plots (Fig 3) show overall survival HRs and CIs for treatment within selected variable subsets as well as tests of the treatment by variable interactions. The lack of significant interactions suggest no strong evidence for a differential treatment effect between variable levels. One exception is a potential trend for an interaction of sex and histology. Individual plots for sex and histology suggest that treatment did not improve outcome for women or for those with diffuse tumors. Examination of histology pattern by sex revealed some confounding. Nearly twice

Table 1. Second Tumor Sites

Site	No. of Tumor Sites
Radiochemotherapy	25*
Skin	6
Melanoma	2
Colorectal	4
Breast	1
Prostate	4
Hematologic	3
Lymphoma	2
Myelodysplastic syndrome	1
Bladder	3
Lung	1
Renal pelvis	1
Larynx	1
Unknown primary	1
Control	8
Skin	2
Pancreas	2
Breast	1
Lung	1
Hematologic	1
Renal	1

*No. of patients = 21.

Fig 2. (A) Overall survival by arm; (B) relapse-free survival by arm. FU, fluorouracil; RT, radiotherapy.

as many females (56%) had diffuse disease compared with males (30%). Multivariate analysis assessed whether both of these variables were related to outcome. Only histology was significant, suggesting that any effect related to sex may be related to histology rather than to sex itself. The Data Supplement includes selected exploratory subset evaluations by arm. Extreme caution in inter-

pretation is mandatory in view of the low numbers and unplanned subset nature of the data. Evaluation of the D2 group must be tempered by poor statistical power from having small numbers and possible unknown biases influencing selection. The test of treatment interaction for D level was not significant ($P = .53$) and thus does not provide evidence of a lack of treatment benefit for the patients with D2 level of resection. Treatment interaction testing with diffuse histology had $P = .077$. Although not significant at $P < .05$, this raises the question of whether radiochemotherapy improves outcomes in patients with tumors having diffuse histology. In addition to the variables presented in Figure 3, we also explored whether the magnitude of the treatment effect differed depending on the time between surgery and random assignment. We were unable to detect any such effects, either with respect to OS ($P = .47$) or disease-free survival ($P = .71$).

DISCUSSION

This final update of INT-0116 results extends and contextualizes our earlier report.²⁴ Median follow-up for living patients is more than 10 years, and OS and RFS continue to demonstrate dramatic benefit for patients who received adjuvant radiochemotherapy. HRs remain virtually unchanged from our initial report. POF analysis allows several observations. Twenty-four percent more patients in the treatment arm remained free of disease than in the surgery alone arm (nearly twice as many without disease recurrence with radiochemotherapy). This degree of benefit is almost precisely that predicted by the seminal failure pattern analyses of Gunderson and Sosin.⁵ That original work, supported by the work of others,¹³⁻¹⁶ provided the rationale for INT-0116 and observed that 23% of patients experienced treatment failure only in the LRF sites without other sites of relapse. We acknowledge that failure site coding is subject to clinical error, although failure site designation was required at the time of first failure in all patients with relapse. Our POF analysis, however, suggests that our therapy effectively sterilized subclinical LRF sites which would otherwise have resulted in relapse and death. LRF, as defined, was observed much less frequently with radiochemotherapy. However, distant relapse was similar in the treatment and observation groups, suggesting that the improvement in LRF associated with radiochemotherapy may have driven the demonstrated improvement in disease-free survival and OS. Corollaries of this statement are that adjuvant radiochemotherapy should be offered only to those at moderate risk of LRF; further improvements in OS will likely come from improvements in systemic disease control.

Toxicity evaluation demonstrates significant acute morbidity. INT-0116 was activated before serotonin 5-HT₃ receptor antagonists were available. These drugs markedly decrease the nausea and nutritional toxicity of upper abdominal radiochemotherapy.²⁶ The 1% treatment-related mortality seems justified by the substantial OS and RFS benefit. The long follow-up provides some reassurance regarding long-term toxicity. We underscore that the data do not allow evaluation of nonlethal toxicity (eg, hypertension, peptic ulcer disease, or coronary atherosclerosis). Our analyses of treatment effects by patient subsets are exploratory in nature, and must be viewed with caution. In general, the data demonstrate robust benefit of radiochemotherapy in most subsets. Figure 3 shows no statistically significant interactions between any of the variables and treatment effect. Therefore, there is

Table 2. Patterns of Failure by Arm

Relapse Status	Radiochemotherapy		Control (surgery alone)		Total	
	No.	%	No.	%	No.	%
No relapse*	135	48	67	24	202	36
Relapse*	147	52	210	76	357	64
Sites of relapse (% of those randomly assigned)*						
Local	7	2	21	8	28	5
Regional	62	22	109	39	171	31
Distant	46	16	49	18	95	17
Unknown site	32	11	31	11	63	11
Total	282		277		559	

*Indicates statistically significant comparisons. $P < .001$ for relapse v no relapse (χ^2); $P = .012$ for sites of relapse (among those with sites reported, χ^2 test for trend).

Fig 3. Forest plot for overall survival hazard ratios and CIs for treatment within subsets of the selected variables. Hazard ratios greater than one favor the chemoradiation arm. The dotted line represents the overall hazard ratio for treatment benefit.

no compelling evidence that the effect of radiochemotherapy is different among any of these explored treatment variables. Forest plots further provide evidence of the wide-ranging benefit of therapy among the various subsets. Therapy seems beneficial regardless of race, T stage, N stage, or location of the primary within the stomach or GEJ. The exception for histology is interesting and unexplained. Diffuse histology, in most other series, carries a much poorer prognosis occurring in younger, more frequently female patients (all of these associations were described in the original report by Lauren^{24a}). There is evidence that diffuse histology is associated with differences in mucin class, sonic hedgehog profile, gene signature array, and ongoing epidemiologic shift in North America. Whether our observation of reduced treatment effect in patients with diffuse histology is reflective of these biologic variations or is a random observation of an unplanned subset analysis is unknown (histologic type was known in only 77% of patients).

With regard to D resection level and MI, our results support the benefit of radiation. Certainly, those with MI > 5 and D1 or greater nodal surgery (the overwhelming majority of our patients) had markedly improved outcome with radiochemotherapy. Only a small pro-

portion of patients in our data set had MI < 5 surgery (11%) or D2 resection (9.6%). There is no statistically significant interaction of either MI or D strata with therapy, and the HRs favor therapy in both the MI < 5 and D2 cohorts, although with wide confidence intervals. Although MI reflects multiple demographic, T stage, histologic, and other variables in addition to extent of nodal surgery, it does serve as a quantitative estimate of the adequacy of nodal surgery in an individual patient. Every patient included in this study could have had an MI of zero; this variable was under the surgeon's control. Low MI is more likely with more favorable T stage and other variables regardless of nodal resection extent. It is, therefore, not surprising that patients with low MI had improved outcome compared with those with higher MIs. However, by previous multivariate analysis that included T stage and N stage, MI was an independent predictor of survival.²⁵ The RFS and OS curves in the MI < 5 curves show a nonsignificant trend in favor of therapy (for example RFS two-sided $P = .07$). The lack of significant interactions of MI strata and the trend of the MI < 5 subset to benefit from therapy provide assurance that adjuvant radiochemotherapy is reasonable in this group. Likewise, D level shows no significant interaction with treatment. Several studies report that D2 dissection is

more frequently performed in younger, healthier patients,²⁷⁻²⁹ resulting in a potential selection bias likely to produce improved outcome regardless of therapy. In our study, the RFS and OS curves show no trend favoring therapy in the D2 group. Whether this is due to small sample sizes, random fluctuations in subset analyses, or a true clinicopathologic principle is conjectural.

We would comment, regarding INT-0116 surgery, that INT-0116 reflects the real world of gastric surgery performed in North America. Multiple large data sets demonstrate that retrieval of 15 or more nodes in gastric cancer—a suggested surrogate for greater than D1 nodal surgery^{30,31}—is infrequently performed.^{28,31,32} Surgeons' knowledge of quality indicators for gastric surgery is less than optimal,³¹ and evaluations of nodal count suggest minimal increases in recent years.^{33,34} This is understandable in view of the five randomized phase III trials¹⁶⁻²⁰ of nodal resection in gastric cancer (usually D1 v D2 or D2+ comparisons) and a meta-analysis of these randomized trials,³⁵ which uniformly show no OS benefit with more extensive surgery but do show greater mortality and/or morbidity. Furthermore, several reports of D2 surgery continue to observe substantial LRF. The Dutch randomized study^{16,36} reported significant LRF in the D2 arm overall (45%), and in both MI < 5 (27%) and MI 5+ (57%) subsets (autopsy series). Memorial Sloan-Kettering Cancer Center¹⁵ reported LRF in 54% of patients with relapse (76% had D2 or greater resections) and noted no LRF reduction with D2 surgery. Others^{5,37} report continued substantial LRF rates with D2 or greater resection. In contrast, Surveillance, Epidemiology, and End Results (SEER) data show improved survival with adjuvant radiochemotherapy independent of nodal clearance.³² Kim et al³⁸ evaluated 990 patients with D2 dissection and found consistent OS and LRF benefit with adjuvant radiochemotherapy. Therefore, regardless of nodal surgery, some subsets of patients with gastric cancer remain at significant risk of LRF and benefit from radiochemotherapy.

The role of adjuvant radiochemotherapy, used either postoperatively or preoperatively in the setting of effective induction chemotherapy is important to consider. Although several phase III randomized trials^{39,40} and a meta-analysis⁴¹ of all published trials have shown no beneficial effect of induction chemotherapy, the MAGIC trial established perioperative ECF (epirubicin-cisplatin-fluorouracil) chemotherapy as an acceptable standard therapy for resectable lower esophageal and stomach cancer.⁴² HR, RFS, and OS improvements were similar to INT-0116. The composition of the MAGIC cohort is dissimilar to that of the INT-0116 cohort (twice the node-negative incidence, for example), and we emphasize that RFS and OS absolute outcomes cannot be compared across studies. Nevertheless, perioperative chemotherapy is rational, and consideration of adjuvant radiochemotherapy in this context is important. The MAGIC trial noted similar frequency of noncurative (R1-R2) resections in both groups (31% to 34%). R1 resection was especially common in the GEJ (D. Cunningham, personal communication, January 2009). Within a group of patients accrued preoperatively, there will be some subsets at low risk of LRF, rendering radiochemotherapy unreasonable. However, other groups (including uT3,4 GEJ lesions) will have substantial risk of R1-R2 resections and LRF. Preoperative radiochemotherapy may more effectively reduce LRF in these cohorts by improving R0 resection rates. The trial described by Stahl et al⁴⁴ is illustrative of this issue. Patients with lower esophageal/gastric cardia uT3-T4 lesions were randomly assigned to induction chemotherapy alone versus induction chemotherapy

followed by low-dose radiochemotherapy. The addition of radiochemotherapy increased pathologic complete response rate, decreased node positivity, and improved 3-year OS from 28% to 47%. With regard to the high frequency of R1 resection in GEJ tumors noted in the MAGIC trial, Zhang et al⁴⁵ reported improved survival with preoperative radiation alone in a phase III study of 370 patients with GEJ primaries. Similarly, the Gaast et al⁴⁶ trial demonstrated improved OS with preoperative radiochemotherapy versus surgery alone in esophageal and gastroesophageal tumors. The MD Anderson Cancer Center has reported serial phase II studies⁴⁴⁻⁴⁹ of induction chemotherapy followed by radiochemotherapy before resection and observed high R0 resection rate and local control in patient cohorts with unfavorable prognoses. Preoperative radiochemotherapy can, therefore, be judiciously implemented with induction chemotherapy in settings in which induction chemotherapy alone will result in a high R1-R2 rate or in significant LRF after surgery. The current ongoing randomized trials of radiochemotherapy after induction chemotherapy will need to carefully evaluate cohorts with high risk of LRF. INT-0116 accrued only patients at high risk of LRF and established that radiochemotherapy improves locoregional control in such cohorts, which effectively improves RFS and OS. Many issues regarding optimization of radiochemotherapy remain, including optimal timing of radiation with respect to surgery.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a "U" are those for which no compensation was received; those relationships marked with a "C" were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: None **Consultant or Advisory Role:** None **Stock Ownership:** None **Honoraria:** None **Research Funding:** Scott A. Hundahl, Stewart Fund, Pathfinder Fund **Expert Testimony:** None **Other Remuneration:** Scott A. Hundahl, National Cancer Institute

AUTHOR CONTRIBUTIONS

Conception and design: Stephen R. Smalley, Jacqueline K. Benedetti, Daniel G. Haller, Norman C. Estes, Leonard L. Gunderson, James A. Martenson, Grant N. Stemmermann, John S. Macdonald
Administrative support: Jaffer A. Ajani, Grant N. Stemmermann
Provision of study materials or patients: Stephen R. Smalley, Scott A. Hundahl, James A. Martenson, Grant N. Stemmermann
Collection and assembly of data: Stephen R. Smalley, Jacqueline K. Benedetti, Scott A. Hundahl, Bryan Goldman, Grant N. Stemmermann, John S. Macdonald
Data analysis and interpretation: Stephen R. Smalley, Jacqueline K. Benedetti, Scott A. Hundahl, Jaffer A. Ajani, Bryan Goldman, James A. Martenson, J. Milburn Jessup, Grant N. Stemmermann, Charles D. Blanke, John S. Macdonald
Manuscript writing: All authors
Final approval of manuscript: All authors

REFERENCES

1. Wanebo HJ, Kennedy BJ, Chmiel J, et al: Cancer of the stomach. A patient care study by the American College of Surgeons. *Ann Surg* 218:583-592, 1993
2. Hundahl SA, Menck HR, Mansour EG, et al: The National Cancer Data Base report on gastric carcinoma. *Cancer* 80:2333-2341, 1997
3. Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. *Cancer* 88:921-932, 2000
4. Dockerty M: Pathologic aspects of primary malignant neoplasms of the stomach, in ReMine W, Priestley J, Berkson J (eds): *Cancer of the Stomach*. Philadelphia, PA, WB Saunders, 1964, pp 173
5. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. *Int J Radiat Oncol Biol Phys* 8:1-11, 1982
6. Kennedy BJ: TNM classification for stomach cancer. *Cancer* 26:971-983, 1970
7. Mari E, Floriani I, Tinazzi A, et al: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. A study of GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). *Ann Oncol* 11:837-843, 2000
8. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: Revisiting a meta-analysis of randomized trials. *Eur J Cancer* 35:1059-1064, 1999
9. Hermans J, Bonenkamp JJ, Boon MC, et al: Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. *J Clin Oncol* 11:1441-1447, 1993
10. Janunger K, Hafström L, Nygren P, et al: A systematic overview of chemotherapy effects in gastric cancer. *Acta Oncol* 40:309-326, 2001
11. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al: Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis. *JAMA* 303:1729-1737, 2010
12. Shah MA, Ajani JA: Gastric cancer: An enigmatic and heterogeneous disease. *JAMA* 303:1753-1754, 2010
13. Smalley S, Gunderson L: Stomach, in Perez C, Brady L (eds): *Principles and Practice of Radiation Oncology* (ed 3). Philadelphia, PA, Lippincott-Raven, 1996
14. Landry J, Tepper JE, Wood WC, et al: Patterns of failure following curative resection of gastric carcinoma. *Int J Radiat Oncol Biol Phys* 19:1357-1362, 1990
15. D'Angelica M, Gonen M, Brennan MF, et al: Patterns of initial recurrence in completely resected gastric adenocarcinoma. *Ann Surg* 240:808-816, 2004
16. Hartgrink HH, van de Velde CJ, Putter H, et al: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. *J Clin Oncol* 22:2069-2077, 2004
17. Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* 79:1522-1530, 1999
18. Yonemura Y, Wu CC, Fukushima N, et al: Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. *Int J Clin Oncol* 13:132-137, 2008
19. Dent DM, Madden MV, Price SK: Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. *Br J Surg* 75:110-112, 1988
20. Robertson CS, Chung SC, Woods SD, et al: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. *Ann Surg* 220:176-182, 1994
21. Takahashi M, Abe M: Intra-operative radiotherapy for carcinoma of the stomach. *Eur J Surg Oncol* 12:247-250, 1986
22. Moertel CG, Childs DS Jr, Reitemeier RJ, et al: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. *Lancet* 2:865-867, 1969
23. Hallissey MT, Dunn JA, Ward LC, et al: The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: Five-year follow-up. *Lancet* 343:1309-1312, 1994
24. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 345:725-730, 2001
- 24a. Lauren P: The two histologic main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. *Acta Pathol Microbiol Scand* 64:31-49, 1965
25. Hundahl SA, Macdonald JS, Benedetti J, et al: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. *Ann Surg Oncol* 9:278-286, 2002
26. Lévy E, Paillarse JM, Votan B: Efficacy of ondansetron in radiation-induced nausea and vomiting: Review of the literature. *Bull Cancer Radiother* 81:179-185, 1994
27. Dhar DK, Kubota H, Tachibana M, et al: Body mass index determines the success of lymph node dissection and predicts the outcome of gastric carcinoma patients. *Oncology* 59:18-23, 2000
28. Coburn NG, Swallow CJ, Kiss A, et al: Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. *Cancer* 107:2143-2151, 2006
29. Orsenigo E, Tomajer V, Palo SD, et al: Impact of age on postoperative outcomes in 1118 gastric cancer patients undergoing surgical treatment. *Gastric Cancer* 10:39-44, 2007
30. van de Velde C: Resection for gastric cancer in the community. *Semin Oncol* 32:S90-S93, 2005
31. Helyer LK, O'Brien C, Coburn NG, et al: Surgeons' knowledge of quality indicators for gastric cancer surgery. *Gastric Cancer* 10:205-214, 2007
32. Coburn NG, Govindarajan A, Law CH, et al: Stage-specific effect of adjuvant therapy following gastric cancer resection: A population based analysis of 4,041 patients. *Ann Surg Oncol* 15:500-507, 2008
33. Smith DD, Schwarz RR, Schwarz RE: Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: Data from a large US-population database. *J Clin Oncol* 28:7114-7124, 2005
34. Le A, Berger D, Lau M, et al: Secular trends in the use, quality, and outcomes of gastrectomy for noncardia gastric cancer in the United States. *Ann Surg Oncol* 14:2519-2527, 2007
35. McCulloch P, Nita ME, Kazi H, et al: Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. *Cochrane Database Syst Rev* 4:CD001964, 2003
36. Hundahl SA, Peeters KC, Kranenbarg EK, et al: Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer: Autopsy findings form the Dutch D1-D2 Trial. *Gastric Cancer* 10:84-86, 2007
37. Yoo CH, Noh SH, Shin DW, et al: Recurrence following curative resection for gastric carcinoma. *Br J Surg* 87:236-242, 2000
38. Kim S, Lim DH, Lee J, et al: An observational study suggesting clinical benefit for adjuvant post-operative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. *Int J Radiat Oncol Biol Phys* 63:1279-1285, 2005
39. Hartgrink HH, van de Velde CJ, Putter H, et al: Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial. *Eur J Surg Oncol* 30:643-649, 2004
40. Schuhmacher C, Gretschel S, Lordick F, et al: Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organization for Research and Treatment of Cancer Randomized Trial 40954. *J Clin Oncol* 28:5210-5218, 2010
41. Wu AW, Xu GW, Wang HY, et al: Neoadjuvant chemotherapy versus none for resectable gastric cancer. *Cochrane Database Syst Rev* 18:CD005047, 2007
42. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 355:11-20, 2006
43. Reference deleted
44. Stahl M, Walz MK, Stuschke M, et al: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. *J Clin Oncol* 27:851-856, 2009
45. Zhang ZX, Gu XZ, Yin WB, et al: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia (AGC): Report on 370 patients. *Int J Radiat Oncol Biol Phys* 42:929-934, 1998
46. Gaast AV, van Hagen P, Hulshof M, et al: Effect of preoperative concurrent chemoradiotherapy on survival of patient with resectable esophageal or esophagogastric junction cancer: Results from a multicenter randomized phase III study. *J Clin Oncol* 28:302s, 2010 (suppl; abstr 4004)
47. Allal AS, Zwahlen D, Bründler MA, et al: Neoadjuvant radiochemotherapy for locally advanced gastric cancer: Long-term results of a phase I trial. *Int J Radiat Oncol Biol Phys* 63:1286-1289, 2005
48. Ajani JA, Mansfield PF, Janjan N, et al: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. *J Clin Oncol* 22:2774-2780, 2004
49. J.A. Ajani, K. Winter, G.S. Okawara et al.: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. *J Clin Oncol* 24: 3953, 2006.